Abstract: Objective: To evaluate the efficacy and safety of omalizumab in the treatment of normocomplementemic vasculitis (NUV). Methods: The data of 6 patients with NUV treated with omalizumab in our hospital from January 2016 to March 2022 were collected. The efficiency was assessed through Urticarial vasculitis activity score (UVAS) and Dermatology Life Quality Index (DLQI) every 4 weeks. And the related literature were researched and analyzed. Results: A total of 6 patients were enrolled, with treatment duration ranging from 12 weeks to 32 weeks. Two patients with high IgE achieved partial remission at week 4 and complete remission at week 8, while the patients with normal IgE achieved partial remission at week 8 with remission rate of 100%. A dose of 300 mg/4 weeks was found to be more common and effective for the treatment of NUV based on the cases reported previously. There was no adverse reactions was found. Conclusion: Omalizumab is an effective and safe treatment for refractory normocomplementemic vasculitis.

Key words: omalizumab, urticarial vasculitis, refractory